• DOI:10.1093/jnci/djr500
Corpus ID: 17455161

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

@article{Andriole2012ProstateCS,
  title={Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.},
  author={G. Andriole and E. Crawford and R. Grubb and S. Buys and D. Chia and T. Church and M. Fouad and C. Isaacs and P. Kvale and D. Reding and J. Weissfeld and L. Yokochi and B. O'Brien and L. Ragard and J. Clapp and Joshua M. Rathmell and T. Riley and A. Hsing and G. Izmirlian and P. Pinsky and B. Kramer and A. B. Miller and J. Gohagan and P. Prorok},
  journal={Journal of the National Cancer Institute},
  year={2012},
  volume={104 2},
  pages={
          125-32
        }
}

• G. Andriole, E. Crawford, +21 authors P. Prorok
• Published 2012
• Medicine
• Journal of the National Cancer Institute

BACKGROUND The prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was undertaken to determine whether there is a reduction in prostate cancer mortality from screening using serum prostate-specific antigen (PSA) testing and digital rectal examination (DRE). Mortality after 7-10 years of follow-up has been reported previously. We report extended follow-up to 13 years after the trial. METHODS A total of 76 685 men, aged 55-74 years, were enrolled at… Expand

View on PubMed

academic.oup.com

Save to Library

Create Alert

Cite

Launch Research Feed